Perioperative Outcomes and Pathological Response After Neoadjuvant Nivolumab Plus Platinum Chemotherapy in Clinically Node-Negative Non-Small Cell Lung Cancer.
In patients with resectable cN0 NSCLC, nivolumab-based neoadjuvant chemoimmunotherapy was associated with perioperative outcomes and pCR rates similar to those observed in patients with cN1-2, suggesting that this regimen may represent a treatment option for patients with cN0, with careful attention to irAEs and diseas...